Cholangiocarcinoma

The AJMC® Cholangiocarcinoma compendium is a comprehensive resource for clinical news and expert insights about this rare cancer of the bile duct.

Researchers From Spain Find Option to Detect FGFR2 Fusion in Plasma

July 2nd 2022, 2:57pm

Article

Vall d'Hebron Institute of Oncology, a research group from Barcelona, Spain, has presented a method to detect FGFR2 fusion in plasma, which they say is “especially relevant” since the arrival of pemigatinib to treat patients with recurrent intrahepatic cholangiocarcinoma (iCCA).

MSI-High Status Linked With PD-1 Therapy Response in Cholangiocarcinoma

June 24th 2022, 6:54pm

Article

Just 5% of patients in a cholangiocarcinoma cohort were categorized as microsatellite instability high (MSI-high), but those patients tended to have “excellent” responses to therapy.

Progress Made in Classifying iCCA, but Challenges Remain, Review Says

June 18th 2022, 11:09am

Article

A dichotomous classification scheme has helped in the intrahepatic cholangiocarcinoma (iCCA) space, but some potential variants require further exploration, the article states.

Combining Techniques Boosts Diagnostic Sensitivity in Intrahepatic Cholangiocarcinoma

June 9th 2022, 6:57pm

Article

Hepatobiliary-phase enhanced imaging outperformed diffusion-weighted imaging in distinguishing intrahepatic mass-forming cholangiocarcinoma, but the accuracy is greater when these methods are used in tandem.

Adjuvant Therapy Shows No Significant Benefits After Cholangiocarcinoma Resection

June 3rd 2022, 2:45pm

Article

A retrospective study found low treatment adherence and no significant benefits to adjuvant chemotherapy or chemoradiotherapy following cholangiocarcinoma resection.

Study Finds Adjuvant Therapy Beneficial for Distal Cholangiocarcinoma With Lymph Node Metastasis

May 29th 2022, 11:30am

Article

Recurrence is common in patients with distal cholangiocarcinoma, even after curative surgical resection. In a recent study, postoperative adjuvant therapy correlated with improved survival, but only in certain patients.

Understanding the Unmet Need for Therapies to Treat Rare Bile Duct Cancer

May 24th 2022, 6:14pm

Podcast

On this episode of Managed Care Cast, we bring you an excerpt of an interview with a co-chair of the 2022 Cholangiocarcinoma Foundation (CCF) annual conference, held earlier this year, about the significant unmet therapy needs facing most patients with this rare cancer.

Alcohol Use, Disease-Free Survival Predictors in Patients With Recurrence of Intrahepatic Cholangiocarcinoma

May 22nd 2022, 3:57am

Article

The study from China sought to evaluate clinical factors associated with survival after recurrence following surgery in ICC.

Biliary Tract Cancer Rates Vary by Country; Prevention Efforts Needed

May 21st 2022, 12:56am

Article

Authors wrote that their analysis was the first to combine incidence and mortality of overall BTC, and its anatomic subtypes, into a single study

City of Hope Faculty Honored for Achievements in Clinical Surgery, Promotion of Women in Cancer Science

May 14th 2022, 10:53pm

Article

Yuman Fong, MD, received the 2022 Flance-Karl Award from the American Surgical Association (ASA), and Leslie Bernstein, PhD, received the Margaret L. Kripke Legend Award for Promotion of Women in Cancer Medicine and Cancer Science.